These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11460392)

  • 1. [Milestone studies provide evidence: sartans have a nephroprotective effect. Evidence is clear].
    Bold KO
    MMW Fortschr Med; 2001 May; 143(22):12-3. PubMed ID: 11460392
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Walser M
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873778
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of hypertension in patients with type 2 diabetes. Sartan also protects the kidneys].
    MMW Fortschr Med; 2001 Aug; 143(31-32):44. PubMed ID: 11556191
    [No Abstract]   [Full Text] [Related]  

  • 4. Preventing nephropathy in patients with type 2 diabetes.
    Manag Care Interface; 2002 Jan; 15(1):72-5. PubMed ID: 11828609
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin II receptor blockers and nephropathy trials.
    Bloomgarden ZT
    Diabetes Care; 2001 Oct; 24(10):1834-8. PubMed ID: 11574450
    [No Abstract]   [Full Text] [Related]  

  • 7. EC approves irbesartan for the treatment of diabetic renal disease.
    Cardiovasc J S Afr; 2002; 13(4):216-7. PubMed ID: 12402931
    [No Abstract]   [Full Text] [Related]  

  • 8. [Organ protection in hypertensive type 2 diabetic patients. Double chance with AT1 blockers].
    MMW Fortschr Med; 2000 Jan; 142(3):58-9. PubMed ID: 10726465
    [No Abstract]   [Full Text] [Related]  

  • 9. [Angiotensin 2 receptor blockaders: how do we explain the kidney-protective effect?].
    Arner P
    Lakartidningen; 2002 Jan; 99(1-2):80-2. PubMed ID: 11871182
    [No Abstract]   [Full Text] [Related]  

  • 10. [Antihypertensive therapy in renal dysfunction].
    Ito S
    Nihon Rinsho; 2003 Jul; 61(7):1210-8. PubMed ID: 12877087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
    Lewis EJ; Hunsicker LG; Clarke WR; Berl T; Pohl MA; Lewis JB; Ritz E; Atkins RC; Rohde R; Raz I;
    N Engl J Med; 2001 Sep; 345(12):851-60. PubMed ID: 11565517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency.
    Descombes E; Fellay G
    Ren Fail; 2000 Nov; 22(6):815-21. PubMed ID: 11104169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prospective treatment study of irbesartan. Diabetic kidneys regain function].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145(41):41. PubMed ID: 14655481
    [No Abstract]   [Full Text] [Related]  

  • 14. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H; Bramlage P; Pittrow D; Kirch W
    MMW Fortschr Med; 2003 Oct; 145 Suppl 3():81-7. PubMed ID: 15490772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diabetic patients have to be tested regularly for microalbuminuria. Almost every second one has already kidney damage].
    MMW Fortschr Med; 2004 Jan; 146(5):47. PubMed ID: 15035422
    [No Abstract]   [Full Text] [Related]  

  • 16. [Observational study of blood pressure control and microalbuminuria in type 2 diabetics on irbesartan or irbesartan/HCTZ].
    Schmieder RE; Krekler M
    MMW Fortschr Med; 2005 Oct; 147 Suppl 3():97-101. PubMed ID: 16261944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical overview of irbesartan: expanding the therapeutic window in hypertension.
    Man in't Veld AJ
    J Hypertens Suppl; 1997 Dec; 15(7):S27-33. PubMed ID: 9532518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
    Parving HH; Lehnert H; Bröchner-Mortensen J; Gomis R; Andersen S; Arner P;
    N Engl J Med; 2001 Sep; 345(12):870-8. PubMed ID: 11565519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evidence based treatment of diabetic nephropathy].
    Sugimoto T
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():294-300. PubMed ID: 12430244
    [No Abstract]   [Full Text] [Related]  

  • 20. Angiotensin-receptor blockers, type 2 diabetes, and renoprotection.
    Ceriello A; Motz E
    N Engl J Med; 2002 Feb; 346(9):705-7. PubMed ID: 11873779
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.